October 16, 2015
Be Proactive,
Not Just Aware

Every October our collective attention turns to breast cancer and suddenly everything turns pink to support “Breast Cancer Awareness”. By now, most every man, woman and child should be aware of breast cancer. In fact with 1 in 8 women developing invasive breast cancer during her lifetime, most people have had someone close to them who was/is directly affected by this disease. Unfortunately, there are still MANY questions and controversies out there about what causes or contributes to breast cancer, what therapies are most effective and confusion about true prevention vs. early detection. In addition to proper screening, there are several steps that all women can take to promote healthy breast tissue and reduce the incidence of breast cancer.

Establish a healthy hormone balance:
Breast tissue is typically very sensitive to hormonal influence and consequently malignancies that arise from these cells are as well. Approximately 80% of breast cancers express estrogen receptors, and 65% have estrogen and progesterone receptors. While it is often assumed that the presence of a hormone receptor indicates that the hormone in question plays a role in the growth of a tumor, recent evidence has indicated that progesterone (through the progesterone receptor) modulates the influence of estrogen and is associated with a positive clinical outcome. Additionally, progesterone has repeatedly been shown to have an inhibitory effect on the growth of normal breast cells. Assessment and treatment of hormone imbalances may not only be a consideration in many breast cancer patients, but is a very important component to an effective breast cancer prevention program.

Avoid or limit chemical endocrine disruptors:
In addition to the correction of endogenous endocrine imbalances, the hormonal sensitive status of breast tissue makes it particularly vulnerable to exogenous chemicals that mimic hormones or otherwise disrupt the endocrine system. Xenoestrogens (estrogen-like molecules that are foreign to the body) are nearly ubiquitous in modern societies and, though the mimicry of estrogen at the estrogen receptor, can increase the growth of breast cancer cells. The attempted avoidance of plasticizers including bisphenol A (BPA) and phthalates, parabens and other common components found in makeup, lotions, sunscreens and other personal hygiene products as well as many insecticides and pesticides that are used in the farming industry is advised for ALL WOMEN for proactive breast cancer prevention.

Maintain a health immune system:
Though there are random cellular mutations that occur in the human body regularly, a health immune system should be able to recognize and shut down these errant growths. The immune system can be compromised by a number of factors including stress and adrenal dysfunction, vitamin and mineral deficiencies and alterations in gut flora. Maintenance of adequate cortisol levels, repletion with nutrients including vitamin D and iodine and establishment of a healthy microbiome can all play a pivotal role in the prevention as well as treatment of breast cancer.

Get current with the latest strategies to assess and treat hormonal imbalances and adrenal dysfunction; join us in Las Vegas in January for our annual Labrix Advanced Workshop. Please visit our website for registration information.

References:
  • http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics
  • http://www.breastcancer.org/symptoms/diagnosis/hormone_status
  • Mohammed et al. Progesterone receptor modulates ERa action in breast cancer. Nature 2015
  • Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC Cohort. Int J Cancer (2005); 114(3):448-54.
  • Desreux J, Kebers F, et al. Progeterone receptor activation – An alternative to SERMs in breast cancer. Eur J Cancer (2000) Sep;36 Suppl 4:S90-1.
  • Malet C, Spritzer P, et al. Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal human breast epithelial (HBE) cells in culture. J Ster Biochem Mol Biol (2002); 73:171-181.
  • Pugazhendhi D, Sadler AJ, Darbre PD (2007). Comparison of the global gene expression profiles produced by methylparaben, n-butylparaben and 17beta-oestradiol in MCF7 human breast cancer cells. J Appl Toxicol 27 (1): 67–77.
  • Darbre PD (March 2006). Environmental oestrogens, cosmetics and breast cancer. Best Pract. Res. Clin. Endocrinol. Metab. 20 (1): 121–43.
  • Darbre PD, Aljarrah A, Miller WR, Coldham NG, Sauer MJ, Pope GS (2004).
  • Sephton SE, Sapolsky RM, Kraemer HC Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. JNCI J Natl Cancer Inst (2000) 92(12): 994-1000.
  • Garland CF. Serum 25¬hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res. 2011 Sep;31(9):2939¬48.
  • Zuan C. Shamonki JM, Chung A et al. Microbial dysbiosis is associated with human breast cancer. PLoS One. 2014 Jan 8:9(1):383744.

Labrix Clinical Spotlight Series:
Hormone and Neurotransmitter Combo Testing

Labrix' Senior Staff Physician Lylen Ferris, ND discusses the benefits of testing both hormones and neurotransmitters to help treat a variety of common physical and mental health concerns.




Labrix Advanced Workshop

Labrix CEO Dr. Erin Lommen extends a personal invitation to providers to come join us at Labrix Advanced Workshop in Las Vegas.



Labrix
Advanced Workshop
Las Vegas, NV
January 16-17, 2016

Join Labrix founders and staff physicians for 2 full days of training and case studies, focusing on hormone, adrenal and neurotransmitter optimization. The workshop is just $199: Register today!

SHEICON
Denver, CO
October 15-18, 2015

Stop by the Labrix booth
at the Seeking Health conference in Denver this weekend, to speak with Labrix CEO and Assoc. Medical Director, Erin Lommen ND, and President, Kate Wells.


IWHIM
Portland, OR
October 16-18, 2015

Labrix physicians, Robyn Kutka ND and Lylen Ferris ND, will be speaking Saturday on the topic of postpartum depression. Labrix will be exhibiting at IWHIM on Friday, Saturday and Sunday.


ACAM
Las Vegas, NV
November 13-15, 2015

Labrix CEO and Assoc. Medical Director, Erin Lommen ND, and Marketing Manager, Angie Daschel, are looking forward to meeting you at ACAM in Las Vegas. Stop by the Labrix booth and pick up the latest treatment protocols and find out what's new.


ITI
Scottsdale, AZ
November 20-21, 2015

Be sure to drop by the exhibit hall at ITI and speak with Labrix President, Kate Wells, at the Labrix booth in Scottsdale.


OANP
Portland, OR
December 5-6, 2015

Labrix is a proud sponsor of the Oregon Association of Naturopathic Physicians. Make plans to attend this annual conference and stop by the booth to meet representatives from Labrix.


A4M
Las Vegas, NV
December 11-13, 2015

Labrix Medical Director, Jay Mead MD and CEO/Assoc. Medical Director, Erin Lommen ND, along with Account Representative, Tom Lasota and Marketing Manager, Angie Daschel will be in the exhibit hall at A4M to answer questions and inform providers about what's new at Labrix.